Business Context and Reporting Period
This Form 8-K filing by JATT Acquisition Corp (JATT) reports on events occurring on January 12, 2023, and January 16, 2023. JATT is a Cayman Islands exempted company and Special Purpose Acquisition Company (SPAC) engaged in a proposed business combination with Zura Bio Limited (Zura). The filing details the results of an Extraordinary General Meeting held to approve an extension of the deadline to consummate this transaction.
Key Financial Metrics and Liquidity
The filing provides specific data regarding shareholder redemptions and trust account liquidity following the Extraordinary General Meeting:
- Redemption Volume: Public shareholders elected to redeem 12,111,022 Class A Ordinary Shares, representing approximately 87.76% of issued and outstanding Class A shares.
- Redemption Price: $10.257 per share.
- Total Redemption Amount: Approximately $124,226,450.64.
- Remaining Trust Account Balance: Approximately $17,324,363.09 (excluding additional interest contributions).
- Remaining Outstanding Shares: 1,688,978 Class A Ordinary Shares.
- Sponsor Contribution: The sponsor deposited $101,338.68 into the Trust Account as additional interest in exchange for an unsecured promissory note.
The filing does not provide revenue, profit, operating cash flow, or debt metrics for Zura Bio or JATT, as this is a transactional report rather than a periodic financial statement.
Material Changes Versus Prior Period
The primary material change reported is the significant reduction in JATT's outstanding share count and trust account liquidity due to the high volume of shareholder redemptions. Additionally, the "Outside Date" (the deadline to consummate the business combination) was extended from January 16, 2023, to April 17, 2023, via a Third Amendment to the Business Combination Agreement.
Guidance, Outlook, and Risks
Outlook and Management Commentary: The filing confirms that shareholders approved the extension of the business combination deadline to April 17, 2023. The sponsor's promissory note of $101,338.68 is repayable only upon the consummation of the business combination and will be forgiven if the deal fails to close by the new deadline (except for funds held outside the Trust Account).
Risks and Contingencies: The filing includes extensive forward-looking statements and risk factors, including:
- Failure to satisfy closing conditions, including the minimum cash requirement following redemptions.
- Inability to obtain necessary regulatory approvals.
- Volatility in securities prices and potential disruption to operations.
- Risks related to Zura's intellectual property, cybersecurity, and the global economic environment.
- The possibility that the business combination will not be completed by the extended deadline.
Investor Verification Checklist
- Verify the final cash balance in the Trust Account against the minimum cash requirement stipulated in the Business Combination Agreement to ensure the deal can proceed.
- Confirm the status of the Third Amendment to the Business Combination Agreement and any remaining closing conditions.
- Review the upcoming Form S-4 registration statement for detailed financial projections and risk factors regarding the combined entity.
- Monitor the timeline for the April 17, 2023, deadline and any potential need for further extensions.
- Assess the impact of the 87.76% redemption rate on the capital structure and future funding needs of the combined company.